P38 MAPK and Radiotherapy: Foes or Friends?

被引:7
|
作者
Garcia-Flores, Natalia [1 ]
Jimenez-Suarez, Jaime [1 ]
Garnes-Garcia, Cristina [1 ]
Fernandez-Aroca, Diego M. [1 ]
Sabater, Sebastia [1 ,2 ]
Andres, Ignacio [1 ,2 ]
Fernandez-Aramburo, Antonio [1 ,3 ]
Ruiz-Hidalgo, Maria Jose [1 ,4 ]
Belandia, Borja [5 ]
Sanchez-Prieto, Ricardo [1 ,5 ,6 ]
Cimas, Francisco J. [1 ,4 ]
机构
[1] Univ Castilla La Mancha, Ctr Reg Invest Biomed, Unidad Med Mol, Unidad Asociada Biomed UCLM,Lab Oncol Mol,Unidad, Albacete 02008, Spain
[2] Complejo Hosp Univ Albacete, Serv Oncol Radioterap, Albacete 02006, Spain
[3] Complejo Hosp Univ Albacete, Serv Oncol Med, Albacete 02006, Spain
[4] Univ Castilla La Mancha, Fac Med, Dept Quim Inorgan Organ & Bioquim, Area Bioquim & Biol Mol, Albacete 02008, Spain
[5] UAM, Inst Invest Biomed Alberto Sols CSIC, Unidad Asociada Biomed UCLM, Unidad Asociada CSIC,Dept Biol Canc, Madrid 28029, Spain
[6] Univ Castilla La Mancha, Fac Med, Dept Ciencias Med, Albacete 02008, Spain
关键词
p38; MAPK; radiation; radiotherapy; MAPK14; cell cycle; ACTIVATED PROTEIN-KINASE; LUNG-CANCER CELLS; RADIATION-INDUCED APOPTOSIS; N-TERMINAL PHOSPHORYLATION; IONIZING-RADIATION; DIFFERENTIAL ACTIVATION; CELLULAR STRESSES; ROS GENERATION; PATHWAY; P38-ALPHA;
D O I
10.3390/cancers15030861
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary p38 MAPKs comprise a family of key proteins that regulate the stress response of human cells, controlling relevant biological phenomena such as the cell cycle. As a result, their role in the cellular response to ionizing radiation and radiotherapy is crucial. In this review, we provide in-depth insights into what is known about the whole protein family's role in response to radiation and the implications for radiotherapy. Over the last 30 years, the study of the cellular response to ionizing radiation (IR) has increased exponentially. Among the various signaling pathways affected by IR, p38 MAPK has been shown to be activated both in vitro and in vivo, with involvement in key processes triggered by IR-mediated genotoxic insult, such as the cell cycle, apoptosis or senescence. However, we do not yet have a definitive clue about the role of p38 MAPK in terms of radioresistance/sensitivity and its potential use to improve current radiotherapy. In this review, we summarize the current knowledge on this family of MAPKs in response to IR as well as in different aspects related to radiotherapy, such as their role in the control of REDOX, fibrosis, and in the radiosensitizing effect of several compounds.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] p38 MAPK in MDS
    Ganan-Gomez, Irene
    Bohannan, Zachary S.
    Garcia-Manero, Guillermo
    AGING-US, 2015, 7 (06): : 346 - 347
  • [2] p38 MAPK inhibitors in COPD
    Macedo, Patricia
    Rhodes, Joann
    Kilty, Iain
    Barnes, Peter
    Donnelly, Louise
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [3] SnapShot: p38 MAPK Signaling
    Trempolec, Natalia
    Dave-Coll, Natalia
    Nebreda, Angel R.
    CELL, 2013, 152 (03) : 656 - +
  • [4] p38 MAPK in development and cancer
    Bradham, Cynthia
    McClay, David R.
    CELL CYCLE, 2006, 5 (08) : 824 - 828
  • [5] Regulation of autophagy by p38α MAPK
    Webber, Jemma L.
    AUTOPHAGY, 2010, 6 (02) : 292 - +
  • [6] Essential Role for p38α MAPK But Not p38γ MAPK in Igf2 Expression and Myoblast Differentiation
    Lovett, Fiona A.
    Cosgrove, Ruth A.
    Gonzalez, Ivelisse
    Pell, Jennifer M.
    ENDOCRINOLOGY, 2010, 151 (09) : 4368 - 4380
  • [7] p38 MAPK Signaling in Osteoblast Differentiation
    Rodriguez-Carballo, Eddie
    Gamez, Beatriz
    Ventura, Francesc
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2016, 4
  • [8] Activin can activate p38 MAPK
    Elena Neumann
    Arthritis Research & Therapy, 3 (1)
  • [9] p38 MAPK in cardioprotection - are we there yet?
    Martin, E. D.
    Bassi, R.
    Marber, M. S.
    BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (08) : 2101 - 2113
  • [10] P38 MAPK regulates COPII recruitment
    Wang, Lijun
    Lucocq, John M.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 363 (02) : 317 - 321